BetriXa 80 Capsule
Betrixaban
80mg
Square Pharmaceuticals PLC.
| Pack size | 10's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 115.00 AED |
Available as:
Indications
BetriXa 80 Capsule is used for:
Venous Thromboembolism Prevention
Adult Dose
Venous Thromboembolism Prevention
Indicated for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for acute medical illness who are at risk for thromboembolic complications owing to moderate or severe restricted mobility and other risk factors for VTE
Initial single dose: 160 mg PO, THEN 80 mg once daily
Recommended duration of treatment: 35-42 days
Child Dose
Renal Dose
Renal impairment
Mild-to-moderate (CrCl >30 mL/min): No dose adjustment is needed
Severe (CrCl >15 to <30 mL/min): Initial single dose of 80 mg, then 40 mg PO qDay x35-42 days
Administration
Take with food at approximately the same time each day
Contra Indications
Active pathological bleeding
Severe hypersensitivity
Precautions
Epidural or spinal hematomas may occur in patients treated with betrixaban who are receiving neuraxial anesthesia or undergoing spinal puncture. The risk of these events may be increased by the use of in-dwelling epidural catheters or the concomitant use of medical products affecting hemostasis. These hematomas may result in longterm or permanent paralysis. Consider these risks when scheduling patients for spinal procedures.
Risk of Bleeding: Can cause serious, potentially fatal bleeding.
Promptly evaluate signs and symptoms of blood loss
Severe Renal Impairment: Increased risk of bleeding events; reduce Betrixaban dose
Concomitant P-gp Inhibitors: Increased risk of bleeding events; reduce Betrixaban dose
Increased Risk of Thrombosis in Patients with Triple-Positive
Antiphospholipid Syndrome: Betrixaban use is not recommended.
Pregnancy-Lactation
Pregnancy
No data exist with use in pregnant women, but treatment is likely to increase risk of hemorrhage during pregnancy and delivery
Use during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus
Animal studies
Although betrixaban has not been associated with adverse developmental fetal outcomes in animals, maternal toxicity (ie, hemorrhage) was identified in these studies
Lactation
Unknown if distributed in human breast milk
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Interactions
Coadministration with drugs affecting hemostasis increases bleeding risk; examples include aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs
P-gp inhibitors increase the blood levels of betrixaban. Reduce betrixaban dose
P-gp inducers may decrease blood levels of betrixaban. Avoid use
Anticoagulants: Avoid concomitant use
Contraindicated (2)
apixaban
rivaroxaban
Serious (8)
caplacizumab
edoxaban
erdafitinib
fondaparinux
lasmiditan
sotorasib
tepotinib
warfarin
Adverse Effects
Side effects of Betrixaban :
1-10%
Clinically relevant nonmajor bleeding (2.45%)
Epistaxis (2%)
Hematuria (2%)
<1%
Bleeding
Major bleeding (0.67%)
GI bleeding (0.51%)
Intracranial hemorrhage (0.05%)
Fatal bleeding (0.03%)
Mechanism of Action
Oral factor Xa (FXa) inhibitor that selectively blocks the active site of FXa and does not require a cofactor (eg, antithrombin III) for activity; inhibits free FXa and prothrombinase activity
By directly inhibiting FXa, betrixaban decreases thrombin generation
Has no direct effect on platelet aggregation
Blood coagulation cascade is dependent upon the activation of factor X to FXa via the intrinsic and extrinsic pathways, which play a central role in the blood coagulation cascade
Note
BetriXa 80 80mg Capsule manufactured by Square Pharmaceuticals PLC.. Its generic name is Betrixaban. BetriXa 80 is availble in Bangladesh.
Farmaco BD drug index information on BetriXa 80 Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.